238 related articles for article (PubMed ID: 35870026)
21. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.
Sriwastava S; Tandon M; Kataria S; Daimee M; Sultan S
J Neurol; 2021 Aug; 268(8):2690-2696. PubMed ID: 33047223
[TBL] [Abstract][Full Text] [Related]
22. Transient acetylcholine receptor-related myasthenia gravis, post multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 infection.
Essajee F; Lishman J; Solomons R; Abraham DR; Goussard P; Van Toorn R
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34380685
[TBL] [Abstract][Full Text] [Related]
23. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
[TBL] [Abstract][Full Text] [Related]
24. Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab.
Damato V; Spagni G; Monte G; Scandiffio L; Cavalcante P; Zampetti N; Fossati M; Falso S; Mantegazza R; Battaglia A; Fattorossi A; Evoli A
Neuromuscul Disord; 2023 Mar; 33(3):288-294. PubMed ID: 36842303
[TBL] [Abstract][Full Text] [Related]
25. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
26. Safety and Immunogenicity of Additional SARS-CoV-2 Vaccinations in a Patient With Myasthenia Gravis on Mycophenolate: A Case Report.
McNeish BL; Colletti RB; Hehir MK
J Clin Neuromuscul Dis; 2022 Dec; 24(2):113-114. PubMed ID: 36409346
[No Abstract] [Full Text] [Related]
27. SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review.
Willison AG; Pawlitzki M; Lunn MP; Willison HJ; Hartung HP; Meuth SG
JAMA Neurol; 2024 Feb; 81(2):179-186. PubMed ID: 38227318
[TBL] [Abstract][Full Text] [Related]
28. The Clinical Course of New-Onset Ocular Myasthenia Gravis Caused by Pfizer-BioNTech COVID-19 Vaccine.
Su WY; Lu CJ
Acta Neurol Taiwan; 2023 Dec; 32(4)():218-222. PubMed ID: 37723915
[TBL] [Abstract][Full Text] [Related]
29. Response to letter to the editor regarding
Maher DI; Hogarty D; Ben Artsi E
Orbit; 2022 Oct; 41(5):662-663. PubMed ID: 35686598
[No Abstract] [Full Text] [Related]
30. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 mRNA Vaccination and Graves' Disease: A Report of 12 Cases and Review of the Literature.
Chee YJ; Liew H; Hoi WH; Lee Y; Lim B; Chin HX; Lai RTR; Koh Y; Tham M; Seow CJ; Quek ZH; Chen AW; Quek TPL; Tan AWK; Dalan R
J Clin Endocrinol Metab; 2022 May; 107(6):e2324-e2330. PubMed ID: 35235663
[TBL] [Abstract][Full Text] [Related]
32. The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.
Peng S; Tian Y; Meng L; Fang R; Chang W; Yang Y; Li S; Shen Q; Ni J; Zhu W
Front Immunol; 2022; 13():1103020. PubMed ID: 36618419
[TBL] [Abstract][Full Text] [Related]
33. Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis.
Tayebi AH; Samimisedeh P; Jafari Afshar E; Ayati A; Ghalehnovi E; Foroutani L; Abbasi Khoshsirat N; Rastad H
Medicine (Baltimore); 2023 Oct; 102(40):e34890. PubMed ID: 37800781
[TBL] [Abstract][Full Text] [Related]
34. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
35. Acute onset ocular myasthenia gravis after COVID-19 vaccination: correspondence.
Mungmunpuntipantip R; Wiwanitkit V
Orbit; 2022 Oct; 41(5):661. PubMed ID: 35639541
[No Abstract] [Full Text] [Related]
36. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
37. COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series.
Ruan Z; Tang Y; Li C; Sun C; Zhu Y; Li Z; Chang T
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696220
[TBL] [Abstract][Full Text] [Related]
38. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine.
Maher DI; Hogarty D; Ben Artsi E
Orbit; 2023 Dec; 42(6):630-634. PubMed ID: 35499172
[TBL] [Abstract][Full Text] [Related]
39. Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.
Lotan I; Hellmann MA; Friedman Y; Stiebel-Kalish H; Steiner I; Wilf-Yarkoni A
Neuromuscul Disord; 2022 Mar; 32(3):230-235. PubMed ID: 35227552
[TBL] [Abstract][Full Text] [Related]
40. Laryngeal myasthenia gravis following influenza vaccination: a case report and literature review.
Wang F; Xiang T; He L; Wang J
Hum Vaccin Immunother; 2021 Dec; 17(12):5529-5531. PubMed ID: 34559977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
